Home/Dyne Therapeutics/Catherine A. Stehman-Breen, MD

CA

Catherine A. Stehman-Breen, MD

Chief Medical Officer

Dyne Therapeutics

Therapeutic Areas

Neuromuscular Diseases Genetic Disorders

Dyne Therapeutics Pipeline

Drug	Indication	Phase
DYNE-101	Myotonic Dystrophy Type 1 (DM1)	Phase 1/2
DYNE-251	Duchenne Muscular Dystrophy (DMD) amenable to exon 51 skipping	Phase 1/2
DYNE-301	Facioscapulohumeral Muscular Dystrophy (FSHD)	Phase 1/2

Leadership Team at Dyne Therapeutics

Joshua T. Brumm

President, Chief Executive Officer & Director

Oxana B. G. Corness

Chief Operating Officer

Susanna M. High

Chief Business Officer

John G. McHutchison, AO, MD

Chief Scientific Officer & Head of R&D

Richard L. Scalzo

Chief Financial Officer

View full Dyne Therapeutics profile